Eton Pharmaceuticals, Inc. (ETON) shares surged 13.8% to close at $42.32, driven by strong trading volume on the last trading session. This follows a 14.5% increase over the past four weeks, fueled by investor optimism about the company’s expanding rare disease portfolio and late-stage pipeline, including products like Amglidia and the Zeneo autoinjector.
The company is projected to report quarterly earnings of $0.13 per share, signaling a 230% year-over-year increase, with revenues expected to reach $27.22 million, up 43.8% from the same quarter last year. Eton holds a Zacks Rank of #3 (Hold).
In a related sector, Celldex Therapeutics (CLDX) closed at $35.35, down 0.1%, with a consensus EPS estimate of -$1.04 for the upcoming report, a 22.4% decline from last year. CLDX also has a Zacks Rank of #3 (Hold).
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
